Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Candriam Equities L Biotechnology

+ Add to Watchlist

DEXLBIC:LX

3,899.46 USD 49.12 1.28%

As of 00:59:30 ET on 04/23/2015.

Snapshot for Candriam Equities L Biotechnology (DEXLBIC)

Year To Date: +18.21% 3-Month: +12.61% 3-Year: +45.30% 52-Week Range: 2,320.19 - 3,960.29
1-Month: +1.02% 1-Year: +60.43% 5-Year: +29.83% Beta vs BTK: 0.95

Mutual Fund Chart for DEXLBIC

No chart data available.
  • DEXLBIC:LX 3,899.46
  • 1M
  • 1Y
Interactive DEXLBIC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DEXLBIC

Candriam Equities L - Biotechnology is a SICAV incorporated under the laws of Luxembourg. The Fund's objective is capital appreciation. The Fund invests in global biotechnology stocks. Because the sector is currently experiencing the highest growth in the U.S., at least two-thirds of the Fund's assets will be invested in U.S. biotechnology stocks.

Inception Date: 03-03-2010 Telephone: 352-254-3431
Managers: RUDI VAN DEN EYNDE
Web Site: www.candriam.com

Fundamentals for DEXLBIC

NAV (on 2015-04-23) 3,899.46
Assets (M) (on 2015-04-23) 882.30
Fund Leveraged N
Minimum Investment 250,000.00
Minimum Subsequent Investment -

Dividends for DEXLBIC

No dividends reported

Fees & Expenses for DEXLBIC

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 0.75
Redemption Fee 0.00
12b1 Fee -
Expense Ratio 0.66

Top Fund Holdings for DEXLBIC

Filing Date: 02/27/2015
Name Position Value % of Total
Biogen Inc 191,000 78,231,690 9.343%
Celgene Corp 520,000 63,195,600 7.548%
Gilead Sciences Inc 550,000 56,941,500 6.801%
Amgen Inc 343,000 54,097,960 6.461%
Regeneron Pharmaceuticals Inc 81,000 33,521,040 4.004%
Alexion Pharmaceuticals Inc 171,000 30,843,270 3.684%
Vertex Pharmaceuticals Inc 204,000 24,363,720 2.910%
Incyte Corp 240,000 20,604,000 2.461%
BioMarin Pharmaceutical Inc 174,000 18,630,180 2.225%
Illumina Inc 95,000 18,568,700 2.218%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil